Oral Administration of Polaprezinc Attenuates Fluorouracil ‐induced Intestinal Mucositis in a Mouse Model

This study aimed to investigate the prophylactic efficacy of Polaprezinc administered orally against intestinal mucositis induced by 5‐FU in mice on the condition that the anti‐tumour effect could not be compromised. We induced intestinal mucositis in SPF grade ICR mice with 5‐FU, and evaluated intestinal damage in the absence or presence of Polaprezinc. We examined the score of diarrhoea and the loss of weight following the 5‐FU treatment, and assessed the integrity of villus and the proliferation of small intestine crypt cells by Hematoxylin&Eosin staining and PCNA immunohistochemical detection. The anti‐tumour effect of 5‐FU on colorectal cancer was assessed with or without Polaprezinc in a xenograft model. The result showed that Polaprezinc significantly reduced the elevated diarrhoea score and the body weight loss caused by 5‐FU, abolished histological abnormality and crypt cell hypoproliferation in a dose‐dependent manner, without affecting 5‐FU efficacy on colon xenograft tumour in mice. We conclude that Polaprezinc could inhibit 5‐FU‐induced diarrhoea and alleviate the weight loss during 5‐FU chemotherapy, as a possible candidate for treatment and prevention of intestinal mucositis, through protecting intestinal mucosa and improving the quality of life following chemotherapy. This article is protected by copyright. All rights reserved.
Source: Basic and Clinical Pharmacology and Toxicology - Category: Drugs & Pharmacology Authors: Tags: Original Article Source Type: research